Form 8-K - Current report:
SEC Accession No. 0001144204-14-001417
Filing Date
2014-01-09
Accepted
2014-01-09 16:31:20
Documents
6
Period of Report
2014-01-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K v365011_8k.htm 8-K 41146
2 EX-4.1 v365011_ex4-1.htm EX-4.1 34191
3 EX-10.1 v365011_ex10-1.htm EX-10.1 124656
4 EX-10.2 v365011_ex10-2.htm EX-10.2 10683
5 EX-10.3 v365011_ex10-3.htm EX-10.3 10846
6 GRAPHIC logo.jpg GRAPHIC 5628
  Complete submission text file 0001144204-14-001417.txt   231009
Mailing Address 3 BETHESDA METRO CENTER SUITE 700 BETHESDA MD 20814
Business Address 3 BETHESDA METRO CENTER SUITE 700 BETHESDA MD 20814 3019611992
REGENERX BIOPHARMACEUTICALS INC (Filer) CIK: 0000707511 (see all company filings)

EIN.: 521253406 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-15070 | Film No.: 14519099
SIC: 2834 Pharmaceutical Preparations